Semaglutide opened the modern era of metabolic peptide research. A ~7-day half-life enabled once-weekly protocols and produced the first double-digit weight-reduction outcomes in the STEP program.
Mechanism
Binds the GLP-1 receptor with high affinity — potentiates glucose-dependent insulin release, delays gastric emptying, modulates hypothalamic appetite signaling. A fatty-acid side chain enables albumin binding and extends half-life.
Published outcomes
- STEP-1: ~14.9% at 68 weeks
- STEP-4: sustained benefit with continued dosing
- SUSTAIN: improved glycemic markers
Related sourcing
- Cagrilintide 10 mg — amylin analog for paired studies
- AOD-9604 5 mg — lipolytic fragment
- Full GLP-1 category
- Comparison with Tirzepatide and Retatrutide
Regional: USA, UK, Canada, France.
> For laboratory and research use only. Not for human consumption, diagnostic, or therapeutic use. All statements below summarize preclinical and academic literature.